DÄ internationalArchiveReferences

Review article

Severe Asthma

Dtsch Arztebl Int 2014; 111: 847-55. DOI: 10.3238/arztebl.2014.0847

Lommatzsch, M; Virchow, J C

1.Sears MR: Trends in the prevalence of asthma. Chest 2014; 145: 219–25. CrossRef MEDLINE
2.Rackemann FM: A clinical study of one hundred and fifty cases of bronchial asthma. Arch Intern Med 1918; 12: 517–52. CrossRef
3.Lommatzsch M, Korn S, Buhl R, Virchow JC: Against all odds: Anti-IgE for intrinsic asthma? Thorax 2014; 69: 94–6. CrossRef MEDLINE PubMed Central
4.Jia CE, Zhang HP, Lv Y, et al.: The asthma control test and asthma control questionnaire for assessing asthma control: Systematic review and meta-analysis. J Allergy Clin Immunol 2013; 131: 695–703. CrossRef MEDLINE
5.Rowe BH, Voaklander DC, Wang D, et al.: Asthma presentations by adults to emergency departments in Alberta, Canada: A large population-based study. Chest 2009; 135: 57–65. CrossRef MEDLINE
6.Bousquet J, Mantzouranis E, Cruz AA, et al.: Uniform definition of asthma severity, control, and exacerbations: Document presented for the World Health Organization consultation on severe asthma. J Allergy Clin Immunol 2010; 126: 926–38. CrossRef MEDLINE
7.Chung KF, Wenzel SE, Brozek JL, et al.: International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43: 343–73. CrossRef MEDLINE
8.Bush A, Pavord ID: Omalizumab: NICE to USE you, to LOSE you NICE. Thorax 2013; 68: 7–8. CrossRef MEDLINE
9.Lommatzsch M, Virchow JC: Asthma-Diagnostik: aktuelle Konzepte und Algorithmen. Allergologie 2012; 35: 454–67. CrossRef
10.To T, Stanojevic S, Moores G, et al.: Global asthma prevalence in adults: Findings from the cross-sectional world health survey. BMC public health 2012; 12: 204. CrossRef MEDLINE PubMed Central
11.Vamos M, Kolbe J: Psychological factors in severe chronic asthma. Aust N Z J Psychiatry 1999; 33: 538–44. CrossRef MEDLINE
12.Heaney LG, Conway E, Kelly C, Gamble J: Prevalence of psychiatric morbidity in a difficult asthma population: Relationship to asthma outcome. Respir Med 2005; 99: 1152–9. CrossRef MEDLINE
13.Katz LE, Gleich GJ, Hartley BF, Yancey SW, Ortega HG: Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma. Ann Am Thorac Soc 2014; 11: 531–6. CrossRef MEDLINE
14.Ortega HG, Liu MC, Pavord ID, et al.: Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014; 371: 1198–207. CrossRef MEDLINE
15.Pavord ID, Korn S, Howarth P, et al.: Mepolizumab for severe eosinophilic asthma (DREAM): A multicentre, double-blind, placebo-controlled trial. Lancet 2012; 380: 651–9. CrossRef MEDLINE
16.Dweik RA, Boggs PB, Erzurum SC, et al.: An official ATS clinical practice guideline: Interpretation of exhaled nitric oxide levels (FeNO) for clinical applications. Am J Respir Crit Care Med 2011; 184: 602–15. CrossRef MEDLINE
17.Buhl R, Berdel D, Criee CP, et al.: [Guidelines for diagnosis and treatment of asthma patients]. Pneumologie 2006; 60: 139–77. CrossRef MEDLINE
18. Abramson MJ, Puy RM, Weiner JM: Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev 2010; CD001186. MEDLINE
19.Kleine-Tebbe J, Bufe A, Ebner C, et al.: Die spezifische Immuntherapie (Hyposensibilisierung) bei IgE-vermittelten allergischen Erkrankungen. Allergo J 2009; 18: 508–37.
20.Castro M, King TS, Kunselman SJ, et al.: Effect of vitamin D3 on asthma treatment failures in adults with symptomatic asthma and lower vitamin D levels: The VIDA randomized clinical trial. JAMA 2014; 311: 2083–91. CrossRef MEDLINE PubMed Central
21.van den Berge M, ten Hacken NH, van der Wiel E, Postma DS: Treatment of the bronchial tree from beginning to end: Targeting small airway inflammation in asthma. Allergy 2013; 68: 16–26. CrossRef MEDLINE
22.Dias-Junior SA, Reis M, de Carvalho-Pinto RM, Stelmach R, Halpern A, Cukier A: Effects of weight loss on asthma control in obese patients with severe asthma. Eur Respir J 2014; 43: 1368–77. CrossRef MEDLINE
23.Bousquet J, Schunemann HJ, Samolinski B, et al.: Allergic rhinitis and its impact on asthma (ARIA): Achievements in 10 years and future needs. J Allergy Clin Immunol 2012; 130: 1049–62. CrossRef MEDLINE
24.Kolbe J, Vamos M, Fergusson W: Socio-economic disadvantage, quality of medical care and admission for acute severe asthma. Aust N Z J Med 1997; 27: 294–300. CrossRef MEDLINE
25.Wainwright NW, Surtees PG, Wareham NJ, Harrison BD: Psychosocial factors and incident asthma hospital admissions in the EPIC-Norfolk cohort study. Allergy 2007; 62: 554–60. CrossRef MEDLINE
26.Rochester CL, Fairburn C, Crouch RH: Pulmonary rehabilitation for respiratory disorders other than chronic obstructive pulmonary disease. Clin Chest Med 2014; 35: 369–89. CrossRef MEDLINE
27.Proskocil BJ, Fryer AD: Beta2-agonist and anticholinergic drugs in the treatment of lung disease. Proc Am Thorac Soc 2005; 2: 305–10; discussion 11–2. CrossRef MEDLINE
28.Kerstjens HA, Disse B, Schroder-Babo W, et al.: Tiotropium improves lung function in patients with severe uncontrolled asthma: A randomized controlled trial. J Allergy Clin Immunol 2011; 128: 308–14. CrossRef MEDLINE
29.Kerstjens HA, Engel M, Dahl R, et al.: Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med 2012; 367: 1198–207. CrossRef MEDLINE
30.Humbert M, Beasley R, Ayres J, et al.: Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60: 309–16. CrossRef MEDLINE
31.Braunstahl GJ, Chen CW, Maykut R, Georgiou P, Peachey G, Bruce J: The experience registry: the ‘real-world' effectiveness of omalizumab in allergic asthma. Respir Med 2013; 107: 1141–51. CrossRef MEDLINE
32.Busse W, Buhl R, Fernandez Vidaurre C, et al.: Omalizumab and the risk of malignancy: Results from a pooled analysis. J Allergy Clin Immunol 2012; 129: 983–9. CrossRef MEDLINE
33.Brusselle GG, Vanderstichele C, Jordens P, et al.: Azithromycin for prevention of exacerbations in severe asthma (AZISAST): A multicentre randomised double-blind placebo-controlled trial. Thorax 2013; 68: 322–9. CrossRef MEDLINE
34.Bousquet J, Aubier M, Sastre J, et al.: Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma. Allergy 2006; 61: 72–8. CrossRef MEDLINE
35.Hambly N, Nair P: Monoclonal antibodies for the treatment of refractory asthma. Curr Opin Pulm Med 2014; 20: 87–94. CrossRef MEDLINE
36.Sachverständigenrat zur Begutachtung der Entwicklung im Gesundheitswesen: www.svr-gesundheit.de, Gutachten 2000/2001, Kurzfassungen Band III (Über-, Unter- und Fehlversorgung), Abschnitt 10.3.2 Asthma.
37.Kowalski ML, Makowska JS, Blanca M, et al.: Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs)—classification, diagnosis and management: Review of the EAACI/ENDA(#) and GA2LEN/HANNA*. Allergy 2011; 66: 818–29. CrossRef MEDLINE
38.Patterson K, Strek ME: Allergic bronchopulmonary aspergillosis. Proc Am Thorac Soc 2010; 7: 237–44. CrossRef MEDLINE
39.Bosch X, Guilabert A, Espinosa G, Mirapeix E: Treatment of antineutrophil cytoplasmic antibody associated vasculitis: A systematic review. JAMA 2007; 298: 655–69. CrossRef MEDLINE
40.Quanjer PH, Brazzale DJ, Boros PW, Pretto JJ: Implications of adopting the global lungs initiative 2012 all-age reference equations for spirometry. Eur Respir J 2013; 42: 1046–54. CrossRef MEDLINE